Mounjaro Injection, Solution
Product Images NDC 0002-1243

Product Visual Gallery

This gallery contains 88 technical images submitted to the FDA as part of the official labeling for Mounjaro (NDC 0002-1243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Moun Uspi Chem Struc)

Chemical structure of tirzepatide, showing its peptide chain with amino acid sequence and attached molecular groups, as provided in the product data for Mounjaro (tirzepatide).*

FDA Label Image

Figure 1 (Moun Uspi F1 V1)

A line graph depicting insulin levels (mIU/L) over time (minutes) comparing tirzepatide 15 mg and placebo at baseline and week 28. The graph shows measurements divided into 1st and 2nd phases, with tirzepatide 15 mg at week 28 displaying a notable rise in insulin levels reaching approximately 225 mIU/L at 120 minutes, contrasting with relatively stable lower levels for placebo and baseline groups.*

FDA Label Image

Figure 2 (Moun Uspi F2 V1)

A line graph comparing HbA1c percentage over 40 weeks post randomization for Mounjaro injection at doses of 5 mg, 10 mg, and 15 mg versus Semaglutide 1 mg. The x-axis shows weeks post randomization and the y-axis shows HbA1c percentage. All Mounjaro doses show a decrease in HbA1c over time, with values slightly lower than Semaglutide at week 40.*

FDA Label Image

Figure 3 (Moun Uspi F3 V1)

A Kaplan-Meier plot comparing the percentage of patients with events over time in weeks from randomization between Mounjaro (tirzepatide) and Dulaglutide. The graph shows cumulative event rates with hazard ratio (HR) 0.92 and 95.3% confidence interval (CI) of 0.83 to 1.01. Patient numbers at risk for both drugs are displayed below the x-axis over the study period.*

FDA Label Image

Figure (Moun Pen Ifu 1 V3)

The image shows a Mounjaro prefilled pen injector for subcutaneous injection. It is a white cylindrical device with a purple cap at one end and a gray needle cover at the other. The label includes dosage indicators and a green dose window. The product contains tirzepatide, manufactured by Eli Lilly and Company.*

FDA Label Image

Figure (Moun Pen Ifu 2 V2)

Illustration of the Mounjaro injection pen components for subcutaneous administration. The labeled parts include the purple injection button at the top, lock ring, indicator, lock or unlock mechanism, visible medicine chamber, clear base, gray base cap, and the bottom and needle end. This diagram shows the injection pen's structure and functional elements.*

FDA Label Image

Figure (Moun Pen Ifu 3 V2)

An illustration showing a Mounjaro injection pen with an arrow pointing to a window area labeled 'Expiration Date,' indicating where the expiration date can be found on the pen.*

FDA Label Image

Figure (Moun Pen Ifu 4a V1)

An illustration showing recommended injection sites for Mounjaro (tirzepatide) subcutaneous injection. The highlighted areas include the abdomen around the belly button and the front parts of both thighs, indicating these as preferred locations for injection administration.*

FDA Label Image

Figure (Moun Pen Ifu 4b V1)

An illustration of a human posterior view highlighting both upper arms in purple, indicating preferred injection sites for a subcutaneous injection. The diagram shows correct areas on the outer arms for administering an injectable medication such as tirzepatide (Mounjaro).*

FDA Label Image

Figure (Moun Pen Ifu 5 V2)

An instructional diagram showing the process of removing the gray base cap from a Mounjaro injection pen with a clear base. The image includes a hand holding the pen, highlighting a lock icon on the pen, and an arrow indicating the gray base cap being detached from the clear base.*

FDA Label Image

Figure (Moun Pen Ifu 6 V2)

An instructional diagram showing the injection of Mounjaro (tirzepatide) subcutaneously into the abdominal area. The illustration depicts a person holding the prefilled injection pen near the abdomen, preparing to administer the dose beneath the skin.*

FDA Label Image

Figure (Moun Pen Ifu 7 V2)

An instructional illustration showing a hand holding a pen-like injection device. The diagram highlights a locking or unlocking mechanism on the device with a rotating arrow and an unlocked padlock icon, indicating the step to unlock or prepare the injection device for use.*

FDA Label Image

Figure (Moun Pen Ifu 8 V2)

Illustration showing a person administering Mounjaro (tirzepatide) injection subcutaneously in the abdominal area. The image demonstrates the proper technique for injecting the solution with the pen device into the skin around the belly.*

FDA Label Image

Figure (Moun Pen Ifu 9 V2)

An illustration showing a close-up view of a gray plunger inside a clear injection device component, labeled with an arrow pointing to the 'Gray Plunger.' This image is likely part of an instructional diagram for the injection system of Mounjaro, a tirzepatide subcutaneous injection by Eli Lilly and Company.*

FDA Label Image

Figure (Moun Pen Ifu 10 V2)

An illustration showing a close-up view of a syringe needle cap with an arrow pointing to the gray plunger inside the cap. The gray plunger is labeled clearly in the image.*

FDA Label Image

Figure (Moun Qr)

FDA Label Image

Figure (Logo)

FDA Label Image

Figure (Moun Vial Ifu 1 V1)

Diagram of a Mounjaro injection vial highlighting the protective cap and rubber stopper under the cap. The vial label shows the product name Mounjaro and the text tirzepatide injection.*

FDA Label Image

Figure (Moun Vial Ifu 2 V1)

Diagram of a syringe injection device with labeled parts including needle shield, needle, plunger tip, plunger, and syringe body. The syringe has volume markings on the body from 0.0 to 1.0 mL, with a magnified inset focused on the 0.5 mL mark for precision measurement.*

FDA Label Image

Figure (Moun Vial Ifu 3 V1)

Illustration showing a hand holding a small vial and another hand removing or lifting off the vial's cap. This instructional image is likely intended to demonstrate how to open or prepare the vial before use.*

FDA Label Image

Figure (Moun Vial Ifu 4 V1)

An instructional illustration showing hands preparing a vial by removing its protective cap. The vial is held steady while one hand peels or lifts the cap off the top, likely demonstrating the initial step of medication preparation for injection.*

FDA Label Image

Figure (Moun Vial Ifu 5 V1)

An instructional illustration showing hands holding and twisting off a needle cap from a syringe or injection pen. The image likely demonstrates a step in preparing a subcutaneous injection, such as for Mounjaro (tirzepatide) injection solution.*

FDA Label Image

Figure (Moun Vial Ifu 6 V1)

An instructional illustration depicting two hands opening a medication vial or cartridge. One hand holds the vial steady while the other removes or peels off a protective seal or cover from the vial's top. The drawing style is simple and clear, aimed at guiding proper preparation of an injection device.*

FDA Label Image

Figure (Moun Vial Ifu 7 V1)

An instructional diagram showing a close-up of a device or pen with a ribbon-like element partially unwrapped around its body. The image suggests a step in the use or preparation process of the device, likely related to the Mounjaro injection pen for subcutaneous administration.*

FDA Label Image

Figure (Moun Vial Ifu 8 V1)

An instructional illustration showing a pair of hands holding a syringe. The illustration includes a left-pointing arrow indicating the direction to pull or remove a component, likely a cap or cover from the syringe prior to use.*

FDA Label Image

Figure (Moun Vial Ifu 9 V1)

An instructional diagram showing a hand holding a syringe filled with a liquid solution, with a downward arrow indicating the direction to push the plunger. The inset zooms in on the syringe barrel, displaying measurement markings from 0.1 to 0.5 mL, illustrating the volume of solution to be administered.*

FDA Label Image

Figure (Moun Vial Ifu 10 V1)

Instructional diagram showing a hand inserting a syringe needle into a vial or ampule, with an arrow indicating the direction of insertion. No specific product labeling is visible.*

FDA Label Image

Figure (Moun Vial Ifu 11 V1)

An instructional illustration showing a pair of hands holding a vial and a syringe. One hand is stabilizing the vial while the other hand is pulling back the syringe plunger to withdraw medication. An arrow indicates the motion of pulling the plunger upward.*

FDA Label Image

Figure (Moun Vial Ifu 12 V1)

Instructional illustration showing a hand holding a syringe vertically with the needle pointing upwards. The plunger is being pressed downward indicated by a large arrow. To the right, a close-up shows the syringe barrel with volume markings from 0.0 to 0.5 mL.*

FDA Label Image

Figure (Moun Vial Ifu 13 V1)

An instructional illustration showing two hands preparing a syringe. One hand holds the syringe upright and the other hand adjusts the plunger or vial, demonstrating how to draw medication into the syringe. There is no visible text or branding in the image.*

FDA Label Image

Figure (Moun Vial Ifu 14 V1)

An instructional illustration showing how to expel air bubbles from a syringe before injection. One hand holds the syringe upright while the other taps the side, with an inset close-up of the syringe barrel markings from 0.1 to 0.5 mL.*

FDA Label Image

Figure (Moun Vial Ifu 15 V1)

An instructional illustration depicting a hand holding a syringe and another hand holding a vial. The syringe needle is positioned near the vial's rubber stopper with an arrow pointing upward, indicating the step of drawing medication from the vial into the syringe. This image relates to preparation for subcutaneous injection.*

FDA Label Image

Figure (Moun Vial Ifu 16 V1)

An anatomical illustration showing recommended subcutaneous injection sites for Mounjaro (tirzepatide) on a human figure. Highlighted areas include the abdomen around the navel and the front and outer sides of both thighs.*

FDA Label Image

Figure (Moun Vial Ifu 17 V1)

An anatomical line drawing showing the back view of a human figure with shaded areas on both upper arms, indicating recommended or typical injection sites, likely for subcutaneous administration of a drug such as Mounjaro (tirzepatide).*

FDA Label Image

Figure (Moun Vial Ifu 18 V1)

An instructional illustration showing the administration of a subcutaneous injection into the abdomen. A hand is holding a syringe with the needle positioned near the skin of the abdominal area, indicating the injection technique for a subcutaneous drug, consistent with usage directions for Mounjaro (tirzepatide) injection.*

FDA Label Image

Figure (Moun Vial Ifu 19 V1)

An instructional illustration showing the administration of a subcutaneous injection into the abdomen. The image depicts a hand holding a syringe at a slight angle to the skin of the lower abdomen, near the waistband of pants.*

FDA Label Image

Figure (Moun Vial Ifu 20 V1)

An instructional black and white line drawing showing a hand holding a syringe with needle inserted in the neck area, indicating a subcutaneous injection technique near the collar region.*

FDA Label Image

Figure (Moun Vial Md Ifu 2 V1)

An instructional diagram illustrating a syringe assembly with labeled parts including the needle shield, needle, plunger tip, syringe body, and plunger. A close-up highlights the volume markings between 0.5 and 0.7 mL on the syringe body scale.*

FDA Label Image

Figure (Moun Vial Md Ifu 9 V1)

An instructional diagram depicting a hand holding a syringe and inserting or pressing it downward, with an inset close-up of the syringe barrel displaying volume markings from 0.1 to 0.6 mL and liquid visible inside, illustrating the correct technique or volume measurement for injection preparation.*

FDA Label Image

Figure (Moun Vial Md Ifu 14 V1)

An instructional illustration showing a person drawing up liquid into a syringe from a vial. The syringe is marked with volume graduations from 0.1 to 0.6 mL, and an upward arrow indicates the direction of fluid withdrawal.*

FDA Label Image

Figure (Mounjaro Kp 1 Pen V1)

Mounjaro injection pen device for subcutaneous administration. The device is white with a dose window displaying the number '0' and a purple dose selector knob at the end, consistent with Eli Lilly and Company's Mounjaro tirzepatide injection pens available in various strengths.*

FDA Label Image

Figure (Mounjaro Kp 2 Pen Parts V2)

An illustrated diagram labeling the parts of a Mounjaro injectable pen device for subcutaneous use. Components shown include the pen cap with cap clip, cartridge with plunger inside the cartridge holder, pen body with label, dose indicator visible through the dose window, and dose knob. Additional labeled pen needle parts, not included in the device, are the outer needle shield, inner needle shield, needle, and paper tab. A red inner seal on the cartridge is also shown.*

FDA Label Image

Figure (Mounjaro Kp 3 Wash V1)

An instructional black-and-white illustration showing two hands with soap bubbles, depicting the action of hand washing or hand cleansing.*

FDA Label Image

Figure (Mounjaro Kp 4 Uncap V1)

An instructional illustration showing a pen-type injection device with its cap and a red arrow pointing left, indicating removal of the cap from the injection pen. The image is related to the Mounjaro (tirzepatide) subcutaneous injection solution.*

FDA Label Image

Figure (Mounjaro Kp 5 Wipe V1)

An instructional illustration showing hands removing a cap or seal from the top of an injection pen or vial, with a red arrow indicating the direction of removal. No specific product branding is visible.*

FDA Label Image

Figure (Mounjaro Kp 6 New Needle Tab V1)

An instructional illustration demonstrating the proper technique to remove a cap from a vial or similar container, showing a hand gripping and lifting the cap upwards with a red arrow indicating the direction of removal.*

FDA Label Image

Figure (Mounjaro Kp 7 Attach Needle V1)

An instructional diagram showing the twisting or locking mechanism of a pen injector device. The image illustrates how to rotate the pen cap or dial, indicated by red arrows, likely as part of the preparation or dosing adjustment process for a subcutaneous injection device.*

FDA Label Image

Figure (Mounjaro Kp 8 Outer Shield V1)

An instructional illustration showing the removal of a protective cap from an injection pen. The image depicts the pen’s needle section with an arrow pointing upward, indicating that the cap should be pulled off straight to expose the needle for subcutaneous injection.*

FDA Label Image

Figure (Mounjaro Kp 9 Inner Shield V1)

An instructional illustration showing a syringe with a needle cap being removed by pulling upward, indicated by a red arrow pointing away from the needle. This image likely demonstrates how to prepare the injection device for use.*

FDA Label Image

Figure (Mounjaro Kp 10 Dial Clicks V1)

An instructional illustration showing a hand peeling back a tab or label on a surface, indicated by a downward arrow to demonstrate the motion needed for removal or opening.*

FDA Label Image

Figure (Mounjaro Kp 11 Dial Zoom V1)

Packaging label for Mounjaro 7.5 mg/0.5 mL injection, solution in a subcutaneous single-dose pen. The label includes the proprietary name Mounjaro, strength 7.5 mg/0.5 mL, and Eli Lilly and Company as the labeler. The label is primarily in red and white with barcode and regulatory symbols.*

FDA Label Image

Figure (Mounjaro Kp 12 Tap V1)

An instructional illustration depicting a hand holding a syringe vertically while tapping the side of the syringe barrel with the index finger of the other hand. The image includes an arrow pointing toward the syringe tip, suggesting the action of moving air bubbles upward before injection.*

FDA Label Image

Figure (Mounjaro Kp 13 5sec Hold V1)

An instructional illustration showing a hand holding a syringe-like injection pen with a needle cap removal indicated by an upward arrow. The inset depicts a close-up of the pen needle tip. A stopwatch icon suggests a waiting time after needle cap removal, likely related to preparation or priming before injection.*

FDA Label Image

Figure (Mounjaro Kp 14 Zero Dial Zoom V1)

Mounjaro injection, solution, 7.5 mg/0.5 mL in a single-dose prefilled pen. Label indicates the product is manufactured by Eli Lilly and Company. The label includes dosing instructions, storage information, and safety warnings typical of a prescription injectable medication for subcutaneous use.*

FDA Label Image

Figure (Mounjaro Kp 15 Inj Sites V1)

Illustration showing recommended injection sites for Mounjaro (tirzepatide) injection. Areas highlighted include the abdomen, front and side of the thighs, and the upper arms, indicating subcutaneous administration locations for the solution dosage form.*

FDA Label Image

Figure (Mounjaro Kp 16 Dial 1 Dose V1)

An instructional illustration showing a hand dialing the dosage selector on a pen injector device. The image features arrows indicating the direction to turn the dial, demonstrating how to set the dose for subcutaneous injection.*

FDA Label Image

Figure (Mounjaro Kp 17 Dial 1 Zoom V1)

Mounjaro 1 mg vial label visible with tirzepatide as the active ingredient for subcutaneous injection. Label includes dose strength and usage instructions. Manufactured by Eli Lilly and Company.*

FDA Label Image

Figure (Mounjaro Kp 18 Insert Needle V1)

An instructional illustration showing a hand holding a prefilled injection pen near the thigh, with an arrow indicating the direction of subcutaneous injection into the thigh area.*

FDA Label Image

Figure (Mounjaro Kp 19 Push Hold V1)

An instructional illustration showing a person holding a syringe-style pen for injection. The image includes a red arrow labeled 'PUSH' indicating to press the injection button and a stopwatch symbol with the text '5 sec. HOLD,' instructing the user to hold the injection for five seconds after pushing.*

FDA Label Image

Figure (Mounjaro Kp 20 Remove V1)

An instructional illustration showing a person holding an injection pen near the abdomen. The image includes a directional arrow pointing leftward, suggesting the motion or direction in which to use the injection device for subcutaneous administration.*

FDA Label Image

Figure (Mounjaro Kp 21 Cotton Ball V1)

Illustration showing a hand holding the injection site on the abdomen for subcutaneous administration. The image demonstrates where to insert the injection needle, indicated by a red arrow pointing to the skin area.*

FDA Label Image

Figure (Mounjaro Kp 22 Recap Shield V1)

An instructional illustration showing a hand removing the protective cap from the needle of an injection pen device, indicated by a red arrow pointing away from the pen. The image is related to the preparation for subcutaneous injection.*

FDA Label Image

Figure (Mounjaro Kp 23 Remove Needle V1)

An instructional illustration showing a hand removing a protective cap from the tip of a pen injection device, with a red arrow indicating the direction of cap removal. This is likely related to preparation for subcutaneous injection of a medication such as Mounjaro (tirzepatide) injection.*

FDA Label Image

Figure (Mounjaro Kp 24 Recap Pen V1)

An instructional illustration showing a pen-style injection device with its cap being removed by pulling it straight off, indicated by a red arrow pointing away from the device.*

FDA Label Image

Package Label (Mounjaro Prefilled Pen (Autoinjector))

Mounjaro 2.5 mg/0.5 mL (tirzepatide) injection carton label for subcutaneous use by Eli Lilly and Company. The packaging contains 4 single-dose prefilled pens, indicated for weekly use. The label displays the strength prominently along with an image of a prefilled pen and instructions indicating it is Rx only.*

FDA Label Image

Package Label (Mounjaro Prefilled Pen (Autoinjector))

Packaging label for Mounjaro 5 mg/0.5 mL (tirzepatide) injection, a subcutaneous injection by Eli Lilly and Company. The label indicates a package containing 4 single-dose prefilled pens, with instructions for weekly use. The label features the Mounjaro logo, strength, dosage form, and manufacturer information.*

FDA Label Image

Package Label (Mounjaro Prefilled Pen (Autoinjector))

Packaging label for Mounjaro 7.5 mg/0.5 mL injection by Eli Lilly and Company. The label indicates 4 single-dose prefilled pens for subcutaneous use. The product name, strength, and dosage form are prominently displayed, along with an image of a single prefilled pen. The label includes prescribing and usage advisories and the NDC 0002-1484-80.*

FDA Label Image

Package Label (Mounjaro Prefilled Pen (Autoinjector))

Packaging label for Mounjaro (tirzepatide) injection 10 mg/0.5 mL by Eli Lilly and Company. The label shows 4 single-dose prefilled pens with instructions for subcutaneous use and prescription only. The label highlights the product name, strength, dosage form, and includes a visual of the injection pen.*

FDA Label Image

Package Label (Mounjaro Prefilled Pen (Autoinjector))

Mounjaro 12.5 mg/0.5 mL (tirzepatide) injection box label for subcutaneous use by Eli Lilly and Company. The package contains 4 single-dose prefilled pens. The front displays instructions to use one pen every week, with a product image and the Lilly logo.*

FDA Label Image

Package Label (Mounjaro Prefilled Pen (Autoinjector))

Packaging label for Mounjaro (tirzepatide) injection, 15 mg/0.5 mL, by Eli Lilly and Company. The label indicates the product is a subcutaneous injection supplied as 4 single-dose prefilled pens. The front panel includes dosage strength, product name, usage instructions to use one pen weekly, and a visual of the prefilled pen.*

FDA Label Image

Package Label (Mounjaro Single-Dose Vial)

Mounjaro (tirzepatide) injection 2.5 mg/0.5 mL carton by Eli Lilly and Company. The label shows a single-dose vial for subcutaneous use, marked Rx only, with instructions to discard unused portions. It states no preservatives and no U.S. standard of potency. The packaging includes storage information, marketing details by Lilly USA, LLC, and a barcode.*

FDA Label Image

Package Label (Mounjaro Single-Dose Vial)

Packaging label for Mounjaro (tirzepatide) injection, 5 mg/0.5 mL, a subcutaneous solution by Eli Lilly and Company. The label includes storage instructions, dosage information, and states it is a single-dose vial for subcutaneous use. The NDC 0002-1243-01 is visible along with branding and an indication to dispense the Medication Guide with each patient.*

FDA Label Image

Package Label (Mounjaro Single-Dose Vial)

Mounjaro 7.5 mg/0.5 mL injection solution label for subcutaneous use by Eli Lilly and Company. The single-dose vial label states it contains tirzepatide and includes storage instructions, dosage details, and a barcode. The box warns to store refrigerated at 2°C to 8°C, protect from light, and discard unused portion after 21 days. No preservatives or U.S. potency standard are indicated.*

FDA Label Image

Package Label (Mounjaro Single-Dose Vial)

Packaging label for Mounjaro 10 mg/0.5 mL (tirzepatide) injection by Eli Lilly and Company. The label indicates the product is a single-dose vial for subcutaneous use, with storage instructions to keep refrigerated at 2°C to 8°C and not to freeze. The label also states that needles and syringes are not included and instructs to dispense the enclosed medication guide to each patient.*

FDA Label Image

Package Label (Mounjaro Single-Dose Vial)

Packaging label for Mounjaro (tirzepatide) injection, solution 12.5 mg/0.5 mL by Eli Lilly and Company. The label indicates a single-dose vial for subcutaneous use, Rx only, with storage instructions and a note that needles and syringes are not included. It includes dosage information, a barcode, and the requirement to dispense the enclosed Medication Guide to each patient.*

FDA Label Image

Package Label (Mounjaro Single-Dose Vial)

The packaging label for Mounjaro (tirzepatide) injection, 15 mg/0.5 mL single-dose vial. The label shows the brand name, dosage strength, and route as subcutaneous injection. It includes storage instructions, stating refrigeration at 2°C to 8°C and a 21-day room temperature storage limit once removed. The product is marketed by Lilly USA, LLC. The label also notes that needles and syringes are not included and instructs to dispense the enclosed medication guide.*

FDA Label Image

Package Label (Mounjaro Multi-Dose Vial)

Packaging label for Mounjaro (tirzepatide) injection, 10 mg/2.4 mL (4.17 mg/mL) multi-dose vial by Eli Lilly and Company. Label includes storage instructions, dosage form as subcutaneous injection, NDC 0002-4052-11, warnings that needles and syringes are not included, and information to dispense the medication guide to patients. The label notes the vial contains 4 doses of 2.5 mg/0.6 mL each. Bar code and manufacturer details are also shown.*

FDA Label Image

Package Label (Mounjaro Multi-Dose Vial)

Mounjaro 20 mg/2.4 mL (8.33 mg/mL) injection label for subcutaneous use by Eli Lilly and Company. The label highlights that the vial contains 4 doses of 5 mg/0.6 mL in a multi-dose vial. It includes storage instructions, a list of inactive ingredients, and a reminder to discard the vial 30 days after first use. The label states that needles and syringes are not included and advises dispensing an enclosed Medication Guide to each patient.*

FDA Label Image

Package Label (Mounjaro Multi-Dose Vial)

Packaging label for Mounjaro (tirzepatide) injection 30 mg/2.4 mL (12.5 mg/mL) by Eli Lilly and Company. Label indicates a 2.4 mL multi-dose vial containing 4 doses of 7.5 mg/0.6 mL each. Instructions emphasize refrigeration or room temperature storage and discarding 30 days after first use. For subcutaneous use, needles and syringes not included.*

FDA Label Image

Package Label (Mounjaro Multi-Dose Vial)

Packaging label for Mounjaro (tirzepatide) injection, 40 mg/2.4 mL (16.7 mg/mL), by Eli Lilly and Company. The label highlights a multi-dose vial containing 4 doses of 10 mg/0.6 mL each. It includes storage instructions, dosage form as subcutaneous injection, and notes that needles and syringes are not included. The label also emphasizes dispensing the enclosed Medication Guide to each patient.*

FDA Label Image

Package Label (Mounjaro Multi-Dose Vial)

Label for Mounjaro (tirzepatide) injection, 50 mg/2.4 mL (20.8 mg/mL) multi-dose vial by Eli Lilly and Company. The label includes usage instructions, storage warnings to refrigerate and avoid freezing, and highlights that the vial contains 4 doses of 12.5 mg/0.6 mL. It specifies subcutaneous use, notes that needles and syringes are not included, and instructs dispensing the enclosed Medication Guide to each patient.*

FDA Label Image

Package Label (Mounjaro Multi-Dose Vial)

Mounjaro (tirzepatide) injection 60 mg/2.4 mL (25 mg/mL) multi-dose vial packaging label by Eli Lilly and Company. The label states the vial contains 4 doses of 15 mg/0.6 mL, is for subcutaneous use, and notes that needles and syringes are not included. Storage and disposal instructions, dosing information, and a barcode are also visible.*

FDA Label Image

Package Label – Mounjaro Kwikpen – 2.5 mg Per Dose (10 mg/2.4 mL [4.17 mg/ml]) (Moun Cart 2point5mg Kp Nl029)

Mounjaro KwikPen 2.5 mg per dose (10 mg/2.4 mL, 4.17 mg/mL) injection in a single-patient-use KwikPen. The label indicates 1 pen contains 4 doses of 2.5 mg each for subcutaneous use, requiring weekly administration. The label includes storage instructions, dosage knob usage, and manufacturer Eli Lilly and Company information.*

FDA Label Image

Package Label – Mounjaro Kwikpen – 5 mg Per Dose (20 mg/2.4 mL [8.33 mg/ml]) (Moun Cart 5mg Kp Nl030)

Packaging label for Mounjaro KwikPen 5 mg per dose (tirzepatide) injection, a single-patient-use subcutaneous injection pen with 20 mg/2.4 mL (8.33 mg/mL) strength. The label highlights the pen contains 4 doses of 5 mg each, is marketed by Eli Lilly and Company, and provides storage instructions, dosage directions, and safety warnings. The label also notes needles are not included, and it includes barcodes and manufacturer details.*

FDA Label Image

Package Label – Mounjaro Kwikpen – 7.5 mg Per Dose (30 mg/2.4 mL [12.5 mg/ml]) (Moun Cart 7point5mg Kp Nl032)

Packaging label for Mounjaro KwikPen 7.5 mg per dose (tirzepatide) injection, solution for subcutaneous use. This carton contains 1 single-patient-use prefilled pen with 4 doses of 7.5 mg each (30 mg/2.4 mL, 12.5 mg/mL). Labeler is Eli Lilly and Company. The label includes storage instructions, usage details, and a barcode.*

FDA Label Image

Package Label – Mounjaro Kwikpen – 10 mg Per Dose (40 mg/2.4 mL [16.7 mg/ml]) (Moun Cart 10mg Kp Nl026)

Mounjaro KwikPen 10 mg per dose injection solution in a 1 Pen with 4 doses of 10 mg (40 mg/2.4 mL, 16.7 mg/mL) for subcutaneous use. The label instructs to turn the dose knob fully until a '1' is visible, indicating one dose. The carton includes storage instructions, a note that needles are not included, and usage directions. Labeler is Eli Lilly and Company.*

FDA Label Image

Package Label – Mounjaro Kwikpen – 12.5 mg Per Dose (50 mg/2.4 mL [20.8 mg/ml]) (Moun Cart 12point5mg Kp Nl027)

Packaging label for Mounjaro KwikPen (tirzepatide) injection 12.5 mg per dose. The label specifies a single-patient-use KwikPen containing 4 doses of 12.5 mg each in 2.4 mL (20.8 mg/mL) solution for subcutaneous use. The product is labeled by Eli Lilly and Company with NDC 0002-3422-11. Storage instructions, warnings, discard guidance, and carton contents are detailed on the label.*

FDA Label Image

Package Label – Mounjaro Kwikpen – 15 mg Per Dose (60 mg/2.4 mL [25 mg/ml]) (Moun Cart 15mg Kp Nl028)

Packaging label for Mounjaro KwikPen 15 mg per dose (tirzepatide) injection, solution for subcutaneous use. The label shows a single-patient-use pen with 4 doses of 15 mg each, 60 mg/2.4 mL (25 mg/mL) total. Manufactured by Eli Lilly and Company, the label includes usage instructions, storage recommendations, and a note that needles are not included. The pen is intended for once-weekly use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.